LncRNA ZNF593-AS Alleviates Contractile Dysfunction in Dilated Cardiomyopathy
Jiahui Fan,Huaping Li,Rong Xie,Xudong Zhang,Xiang Nie,Xiaolu Shi,Jiabing Zhan,Zhongwei Yin,Yanru Zhao,Beibei Dai,Shuai Yuan,Zheng Wen,Chen Chen,Dao Wen Wang,Jiahui Fan Huaping Li Rong Xie Xudong Zhang Xiang Nie Xiaolu Shi Jiabing Zhan Zhongwei Yin Yanru Zhao Beibei Dai Shuai Yuan Zheng Wen Chen Chen Dao Wen Wang Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,CHINA Hubei Key Laboratory of Genetics and Molecular Mechanism of Cardiologic Disorders,Huazhong University of Science and Technology,CHINA Cardiology,Tongji Hospital,CHINA Experimental Research Center,China Academy of Chinese Medical Sciences,CHINA Tongji Hospital,CHINA Internal Medicine,Tongji Hospital,CHINA
DOI: https://doi.org/10.1161/circresaha.120.318437
IF: 23.213
2021-02-08
Circulation Research
Abstract:Rationale: Previously, we identified the human cardiac long non-coding RNAs (lncRNAs) profile in dilated cardiomyopathy (DCM) patients, among which ZNF593-AS, also named as RP11-96L14.7 and ENST00000448923.2, showed good conservation among species. Objective: We aim to elucidate the mechanism underlying lncRNA in DCM and DCM that lead to heart failure, which might provide new insights into the mechanisms of DCM and possible treatment strategies in the future. Methods and Results: lncRNA expression was measured by real-time PCR and in situ hybridization assays. Coding potential was verified by bioinformatic and biologic assays. Recombinant adeno-associated virus with cardiac specific promoter was used to deliver lncRNA in vivo, while cardiac structure and functions were assessed by echocardiography and catheter. Sarcomere shortening, calcium imaging, gene expression profiling, and pull-down assays were performed to investigate the underlying mechanisms. ZNF593-AS, which mainly localized in the cytoplasm of cardiomyocytes, was robustly decreased in the failing heart of DCM patients, as well as in phenylephrine-treated human cardiomyocytes. Overexpression of mmu-ZNF593-AS significantly improved transverse aortic constriction (TAC)-induced cardiac dysfunction in mice. Moreover, ZNF593-AS overexpression restored the aberrant Ca 2+ handling and contractility of cardiomyocytes from TAC-treated mice. Further, we found that ZNF593-AS acted as a guide RNA scaffold and recruited HNRNPC to ryanodine receptor type 2 (RYR2) mRNA, which in turn facilitated RYR2 mRNA stability, contributed to the improvement of cardiac Ca 2+ handling and contractile function in DCM. Conclusions: Our findings suggested that lncRNA-based therapeutics may protect against DCM.
cardiac & cardiovascular systems,peripheral vascular disease,hematology